Systemic Lupus Erythematosus Clinical Trials in Oklahoma City, Oklahoma

6 studies are recruiting for systemic lupus erythematosus in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

   This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are pu…

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

   Locations

   140 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07409181 on ClinicalTrials.gov

2. A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

   The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Research Site, Oklahoma City, Oklahoma

   Locations

   107 in total

   Run by

   AstraZeneca

   See if you can join NCT07430306 on ClinicalTrials.gov

3. Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

   Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, …

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

   Locations

   12 in total

   Run by

   NYU Langone Health

   See if you can join NCT05799378 on ClinicalTrials.gov

4. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

   This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung diseas…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   GSK Investigational Site, Oklahoma City, Oklahoma

   Locations

   28 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06576271 on ClinicalTrials.gov

5. Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

   The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in pat…

   Stage

   Not phased

   Ages

   18 to 45

   Site

   Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

   Locations

   10 in total

   Run by

   Hospital for Special Surgery, New York

   See if you can join NCT00198068 on ClinicalTrials.gov

6. Safety of the Herpes Zoster Subunit Vaccine in Lupus

   This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The …

   Stage

   Phase 4

   Ages

   18 to 90

   Site

   Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

   Locations

   2 in total

   Run by

   NYU Langone Health

   See if you can join NCT05559671 on ClinicalTrials.gov